Literature DB >> 9258262

Amyloid beta-protein (A beta) accumulation in the leptomeninges during aging and in Alzheimer disease.

T Hamano1, M Yoshimura, T Yamazaki, Y Shinkai, K Yanagisawa, M Kuriyama, Y Ihara.   

Abstract

The results of well-characterized two-site enzyme immunoassays showed that the crude leptomeninges (consisting of the pia matter, arachnoid matter, and leptomeningeal vessels [LV]) from aged control brains and brains affected by Alzheimer disease (AD) contain very high levels of amyloid beta-protein (A beta). To learn about the source of A beta, we carefully dissected out both leptomeninges (LM) and LV under a dissecting microscope and determined the levels of soluble A beta in each. The purity of these dissected tissues was confirmed by the absence or presence of alpha-smooth muscle actin representing LV by Western blotting. Surprisingly, the amounts of A beta in each dissected sample were nearly equivalent on a weight basis. In each compartment from aged controls the level of A beta 1-42 was comparable to that of A beta 1-40, while in AD brain A beta 1-40 was a predominant species in both LM and LV. In some cases careful immunocytochemical examination revealed the presence of A beta deposits that were immunolabeled by several A beta monoclonal antibodies in leptomeningeal layers (most often in the arachnoid matter). The extent of A beta deposition in LM appeared to be much less than that explained by the soluble A beta levels, suggesting that immunocytochemically undetectable A beta can accumulate in LM. These observations indicate that leptomeninges are a large reservoir of A beta in normal aged individuals and in AD patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9258262     DOI: 10.1097/00005072-199708000-00010

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  7 in total

1.  Rostrocaudal dynamics of CSF biomarkers.

Authors:  Andrew Tarnaris; Ahmed K Toma; Miles D Chapman; Axel Petzold; Geoff Keir; Neil D Kitchen; Laurence D Watkins
Journal:  Neurochem Res       Date:  2010-12-30       Impact factor: 3.996

2.  Vitamin E but not 17beta-estradiol protects against vascular toxicity induced by beta-amyloid wild type and the Dutch amyloid variant.

Authors:  Francisco J Muñoz; Carlos Opazo; Gabriel Gil-Gómez; Gladys Tapia; Virginia Fernández; Miguel A Valverde; Nibaldo C Inestrosa
Journal:  J Neurosci       Date:  2002-04-15       Impact factor: 6.167

3.  Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease.

Authors:  H Funato; M Yoshimura; K Kusui; A Tamaoka; K Ishikawa; N Ohkoshi; K Namekata; R Okeda; Y Ihara
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

4.  Studying Human Brain Inflammation in Leptomeningeal and Choroid Plexus Explant Cultures.

Authors:  Mike Dragunow; Sheryl Feng; Justin Rustenhoven; Maurice Curtis; Richard Faull
Journal:  Neurochem Res       Date:  2015-08-05       Impact factor: 3.996

5.  Elevated cerebrospinal fluid pressure in patients with Alzheimer's disease.

Authors:  Gerald Silverberg; Martha Mayo; Thomas Saul; Jere Fellmann; Dawn McGuire
Journal:  Cerebrospinal Fluid Res       Date:  2006-05-31

6.  Structural and functional conservation of non-lumenized lymphatic endothelial cells in the mammalian leptomeninges.

Authors:  Shannon Shibata-Germanos; James R Goodman; Alan Grieg; Chintan A Trivedi; Bridget C Benson; Sandrine C Foti; Ana Faro; Raphael F P Castellan; Rosa Maria Correra; Melissa Barber; Christiana Ruhrberg; Roy O Weller; Tammaryn Lashley; Jeffrey J Iliff; Thomas A Hawkins; Jason Rihel
Journal:  Acta Neuropathol       Date:  2019-11-06       Impact factor: 17.088

7.  Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors.

Authors:  Derek R Johnson; Christopher H Hunt; Mark A Nathan; Joseph E Parisi; Bradley F Boeve; Melissa E Murray; David S Knopman; Clifford R Jack; Ronald C Petersen; Val J Lowe; Geoffrey B Johnson
Journal:  J Neurooncol       Date:  2017-11-08       Impact factor: 4.130

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.